EFG Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.4M | Buy |
11,175
+1,026
| +10% | +$129K | 0.2% | 154 |
|
|
2025
Q1 | $1.12M | Sell |
10,149
-3,172
| -24% | -$351K | 0.19% | 166 |
|
|
2024
Q4 | $1.82M | Sell |
13,321
-14,190
| -52% | -$1.94M | 0.25% | 164 |
|
|
2024
Q3 | $3.17M | Sell |
27,511
-5,589
| -17% | -$644K | 0.53% | 61 |
|
|
2024
Q2 | $4.56M | Sell |
33,100
-2,764
| -8% | -$381K | 0.79% | 25 |
|
|
2024
Q1 | $4.94M | Sell |
35,864
-637
| -2% | -$87.8K | 0.85% | 24 |
|
|
2023
Q4 | $4.81M | Sell |
36,501
-1,627
| -4% | -$214K | 0.91% | 21 |
|
|
2023
Q3 | $4.29M | Buy |
38,128
+390
| +1% | +$43.9K | 1.02% | 27 |
|
|
2023
Q2 | $3.56M | Buy |
37,738
+3,743
| +11% | +$353K | 0.76% | 49 |
|
|
2023
Q1 | $3.44M | Buy |
33,995
+4,465
| +15% | +$452K | 0.76% | 46 |
|
|
2022
Q4 | $3.55M | Sell |
29,530
-1,139
| -4% | -$137K | 0.8% | 40 |
|
|
2022
Q3 | $3.26M | Sell |
30,669
-2,692
| -8% | -$286K | 0.75% | 46 |
|
|
2022
Q2 | $3.25M | Buy |
33,361
+2,278
| +7% | +$222K | 0.68% | 48 |
|
|
2022
Q1 | $2.92M | Buy |
+31,083
| New | +$2.92M | 0.44% | 66 |
|